Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1071 participants.
Also called NCT01033071
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,071 participants
- Sponsor
- Registry
-
NCT01033071 -
U1111-1112-4298
-
- Other papers using this trial's data
- Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01033071. Randomized; quadruple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results posted on 2012-02-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
- Condition
- Essential Hypertension
- Intervention (Drug)
- Azilsartan medoxomil and chlorthalidone
- Intervention (Drug)
- Azilsartan medoxomil and chlorthalidone
- Intervention (Drug)
- Olmesartan medoxomil and hydrochlorothiazide
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01033071- Content hash
8d5f62ae070237de13d7d9c18a917ee1f24d1dd08f97bd403fce2046585064a6